Login to Your Account



Merck inks immunotherapy links with Dynavax, Tesaro during ASCO

By Michael Fitzhugh
Staff Writer

Monday, June 1, 2015
CHICAGO – Merck & Co. Inc. and Dynavax Technologies Corp. have agreed to pursue dual trials investigating the potential for combining immunotherapies from both companies' pipelines to help patients with multiple cancers

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription